SAB Biotherapeutics, Inc. (SABS)
NASDAQ: SABS · Real-Time Price · USD
3.200
+0.250 (8.47%)
Nov 18, 2026, 4:00 PM EST - Market closed
SAB Biotherapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
86
Market Cap
288.28M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | 1.32M | -916.58K | -40.94% |
| Dec 31, 2023 | 2.24M | -21.67M | -90.63% |
| Dec 31, 2022 | 23.90M | -36.97M | -60.73% |
| Dec 31, 2021 | 60.88M | 5.64M | 10.21% |
| Dec 31, 2020 | 55.24M | 51.80M | 1,504.91% |
| Dec 31, 2019 | 3.44M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Agenus | 133.95M |
| Protalix BioTherapeutics | 84.69M |
| Fulcrum Therapeutics | 80.00M |
| Precision BioSciences | 45.04M |
| Evommune | 10.00M |
| Ocugen | 4.78M |
| Allogene Therapeutics | 4.64M |
| Inovio Pharmaceuticals | 298.90K |
SABS News
- 1 day ago - SAB Biotherapeutics Transcript: UBS Global Biopharma Conference 2026 - Transcripts
- 2 days ago - SAB Biotherapeutics Transcript: Jefferies Global Healthcare Conference - Transcripts
- 9 days ago - SAB BIO to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 13 days ago - SAB Biotherapeutics reports Q3 EPS (24c), consensus (27c) - TheFly
- 13 days ago - SAB Biotherapeutics Earnings Call Transcript: Q3 2026 - Transcripts
- 13 days ago - SAB Biotherapeutics Earnings release: Q3 2026 - Filings
- 13 days ago - SAB Biotherapeutics Quarterly report: Q3 2026 - Filings
- 13 days ago - SAB BIO Reports Q3 2026 Financial Results and Provides Business Highlights - GlobeNewsWire